- Trial phase
- Approved
- Time to market
- Already approved and commercialized, FDA approval catalyst recorded 2020-11-23; it has been on the market for years.
- Why 3/10
- No hard, dated catalyst for OXLUMO is scheduled in the next ~12 months, its FDA approval already passed years ago, it is a marketed product with no pending regulatory decision, and it is a small slice of Alnylam's revenue, so it lands at 3 on the impact scale.
OXLUMO itself is not a near-term stock driver, do not trade ALNY on it. Watch Alnylam's quarterly earnings for OXLUMO's contribution and the pipeline catalysts that actually move the stock: the cemdisiran NDA (submitted to FDA 2026-04-30 for generalized myasthenia gravis) and zilebesiran/nucresiran readouts; ALNY is currently deeply oversold (RSI ~23.5) after a Q2 2026 EPS/revenue miss and full-year TTR guidance cut.
Price Chart
Executive Summary
OXLUMO is the brand name for lumasiran, Alnylam Pharmaceuticals' FDA-approved RNAi treatment for primary hyperoxaluria type 1, an ultra-rare genetic kidney-stone disease. SecBot records confirm an OXLUMO FDA approval catalyst for ALNY dated 2020-11-23, and Alnylam's Q2 2026 earnings analysis lists OXLUMO as one of its four marketed products, but it is a small, niche contributor next to the TTR franchise (AMVUTTRA alone was ~$1.012B of $1.172B net product revenue in Q2 2026).
How It Works
OXLUMO (lumasiran) is an RNA-interference (RNAi) medicine given by under-the-skin injection that silences a liver gene (HAO1) responsible for generating oxalate, the substance that forms kidney stones. In patients with primary hyperoxaluria type 1, an ultra-rare inherited disease, this cuts oxalate production and lowers the risk of recurrent kidney stones and progressive kidney damage.
Trial Status
Marketed product: SecBot's catalyst/outcome records show an FDA approval for OXLUMO dated 2020-11-23 (stock +0.77% 1-day, +4.14% 5-day around that approval). Alnylam's Q2 2026 earnings filing analysis lists OXLUMO among the company's commercial drugs (with AMVUTTRA, ONPATTRO, GIVLAARI). No open Phase 2/3 lumasiran trials appeared in SecBot's ClinicalTrials.gov-ingested pipeline records.
The Two-Sided Case
Upcoming Catalysts
- None scheduled for OXLUMO itself.
- Company-level catalysts that move ALNY instead: cemdisiran NDA (submitted 2026-04-30 for generalized myasthenia gravis) and pipeline readouts for zilebesiran, nucresiran and mivelsiran.
- Quarterly earnings (Q2 2026 reported 2026-07-30; guidance cut bears watching) for OXLUMO's contribution to the product revenue mix.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report